Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMATCH: Intensive Glycemic Control Strategies in T2D
NCT06627322Recruiting
- Start
- Nov 2024
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
Randomised, open-label trial in type 2 diabetes mellitus (T2DM) (2 arms). Primary endpoint: Composite of major adverse cardiovascular events (MACE) or diabetic microvascular events at 4 years. Started Nov 2024; status: recruiting.
02
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06627322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06627322.